Aliases & Classifications for Fainting

MalaCards integrated aliases for Fainting:

Name: Fainting 53 42

Summaries for Fainting

NINDS : 53 Syncope is a medical term used to describe a temporary loss of consciousness due to the sudden decline of blood flow to the brain. Syncope is commonly called fainting or “passing out.” If an individual is about to faint, he or she will feel dizzy, lightheaded, or nauseous and their field of vision may “white out” or “black out.”  The skin may be cold and clammy.  The person drops to the floor as he or she loses consciousness.  After fainting, an individual may be unconscious for a minute or two, but will revive and slowly return to normal.  Syncope can occur in otherwise healthy people and affects all age groups, but occurs more often in the elderly.  There are several types of syncope.  Vasovagal syncope usually has an easily identified triggering event such as emotional stress, trauma, pain, the sight of blood, or prolonged standing.  Carotid sinus syncope happens because of constriction of the carotid artery in the neck and can occur after turning the head, while shaving, or when wearing a tight collar.  Situational syncope happens during urination, defecation, coughing, or as a result of gastrointestinal stimulation.  Syncope can also be a symptom of heart disease or abnormalities that create an uneven heart rate or rhythm that temporarily affect blood volume and its distribution in the body.  Syncope isn’t normally a primary sign of a neurological disorder, but it may indicate an increased risk for neurologic disorders such as Parkinson’s disease, postural orthostatic tachycardia syndrome (POTS), diabetic neuropathy, and other types of neuropathy.  Certain classes of drugs are associated with an increased risk of syncope, including diuretics, calcium antagonists, ACE inhibitors, nitrates, antipsychotics, antihistamines, levodopa, narcotics, and alcohol.

MalaCards based summary : Fainting is related to ventricular fibrillation, paroxysmal familial, 1 and pediatric angiosarcoma. An important gene associated with Fainting is KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Propranolol and Fludrocortisone have been mentioned in the context of this disorder. Affiliated tissues include heart, brain and skin.

MedlinePlus : 42 Fainting is a temporary loss of consciousness. If you're about to faint, you'll feel dizzy, lightheaded, or nauseous. Your field of vision may "white out" or "black out." Your skin may be cold and clammy. You lose muscle control at the same time, and may fall down. Fainting usually happens when your blood pressure drops suddenly, causing a decrease in blood flow to your brain. It is more common in older people. Some causes of fainting include Heat or dehydration Emotional distress Standing up too quickly Certain medicines Drop in blood sugar Heart problems When someone faints, make sure that the airway is clear and check for breathing. The person should stay lying down for 10-15 minutes. Most people recover completely. Fainting is usually nothing to worry about, but it can sometimes be a sign of a serious problem. If you faint, it's important to see your health care provider and find out why it happened.

Wikipedia : 74 Syncope, also known as fainting, is a loss of consciousness and muscle strength characterized by a fast... more...

Related Diseases for Fainting

Diseases related to Fainting via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 45)
# Related Disease Score Top Affiliating Genes
1 ventricular fibrillation, paroxysmal familial, 1 9.9 KCNH2 CHKB
2 pediatric angiosarcoma 9.8 VWF F8
3 breast hemangioma 9.8 VWF F8
4 lymphangiosarcoma 9.8 VWF F8
5 thyroid angiosarcoma 9.8 VWF F8
6 acquired von willebrand syndrome 9.8 VWF F8
7 von willebrand disease, type 2 9.8 VWF F8
8 pseudo-von willebrand disease 9.8 VWF F8
9 hemarthrosis 9.8 VWF F8
10 angiodysplasia 9.8 VWF F8
11 von willebrand disease, type 3 9.8 VWF F8
12 von willebrand disease, type 1 9.8 VWF F8
13 brachydactyly, type d 9.8 VWF F8
14 intracranial thrombosis 9.8 VWF F8
15 thrombosis 9.8 VWF F8
16 factor v deficiency 9.8 VWF F8
17 thrombophilia due to activated protein c resistance 9.8 VWF F8
18 thrombophilia 9.8 VWF F8
19 factor xiii deficiency 9.8 VWF F8
20 factor viii deficiency 9.7 VWF F8
21 thrombophlebitis 9.7 VWF F8
22 hemophilia a 9.7 VWF F8
23 central retinal vein occlusion 9.7 VWF F8
24 factor xi deficiency 9.7 VWF F8
25 inherited blood coagulation disease 9.7 VWF F8
26 blood coagulation disease 9.7 VWF F8
27 pulmonary artery disease 9.7 VWF F8
28 cardiovascular cancer 9.7 VWF F8
29 vein disease 9.7 VWF F8
30 von willebrand's disease 9.7 VWF F8
31 compartment syndrome 9.7 F8 CHKB
32 hemophilia b 9.7 VWF F8
33 hemorrhagic disease 9.7 VWF F8
34 glanzmann thrombasthenia 9.7 VWF F8
35 afibrinogenemia, congenital 9.6 VWF F8
36 bernard-soulier syndrome 9.6 VWF F8
37 acute myocardial infarction 9.6 VWF CHKB
38 pulmonary embolism 9.6 VWF F8
39 blood platelet disease 9.6 VWF F8
40 atrial fibrillation 9.5 VWF KCNH2
41 cerebrovascular disease 9.4 VWF F8
42 dilated cardiomyopathy 9.3 VWF KCNH2 CHKB
43 hypothyroidism 9.3 VWF F8 CHKB
44 myocardial infarction 9.1 VWF F8 CHKB
45 heart disease 8.9 VWF KCNH2 F8 CHKB

Graphical network of the top 20 diseases related to Fainting:



Diseases related to Fainting

Symptoms & Phenotypes for Fainting

Drugs & Therapeutics for Fainting

Drugs for Fainting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 174)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Propranolol Approved, Investigational Phase 4 525-66-6 4946
2
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Sodium citrate Approved, Investigational Phase 4 68-04-2
5
Metoprolol Approved, Investigational Phase 4 51384-51-1, 37350-58-6 4171
6
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
7
Liraglutide Approved Phase 4 204656-20-2 44147092
8
Empagliflozin Approved Phase 4 864070-44-0
9
Linagliptin Approved Phase 4 668270-12-0 10096344
10
Canagliflozin Approved Phase 4 842133-18-0
11
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
12
Midodrine Approved Phase 4 42794-76-3, 133163-28-7 4195
13
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
14 Narcotics Phase 4
15 Citrate Phase 4
16 Adjuvants, Anesthesia Phase 4
17 Analgesics, Opioid Phase 4
18 Anesthetics, General Phase 4
19 Anesthetics, Intravenous Phase 4
20 Anti-Arrhythmia Agents Phase 4
21 Adrenergic Antagonists Phase 4
22 Neurotransmitter Agents Phase 4
23 Adrenergic beta-Antagonists Phase 4
24 Adrenergic Agents Phase 4
25 Autonomic Agents Phase 4
26 Sodium Channel Blockers Phase 4
27 Diuretics, Potassium Sparing Phase 4
28 Adrenergic beta-1 Receptor Antagonists Phase 4
29 Sympatholytics Phase 4
30 Hypoglycemic Agents Phase 4
31 Lipid Regulating Agents Phase 4
32 Incretins Phase 4
33 HIV Protease Inhibitors Phase 4
34
protease inhibitors Phase 4
35 Anti-Obesity Agents Phase 4
36 Hormone Antagonists Phase 4
37 Sitagliptin Phosphate Phase 4
38 Sodium-Glucose Transporter 2 Inhibitors Phase 4
39 Dipeptidyl-Peptidase IV Inhibitors Phase 4
40 Sympathomimetics Phase 4
41 Vasoconstrictor Agents Phase 4
42
Norepinephrine Approved Phase 3 51-41-2 439260
43
Parathyroid hormone Approved, Investigational Phase 3 9002-64-6
44
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
45 Calcium, Dietary Phase 3
46
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
47
Ethanol Approved Phase 2 64-17-5 702
48
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
49
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
50
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II) Completed NCT00118482 Phase 4 fludrocortisone acetate
2 Syncope: Pacing or Recording in the Later Years (SPRITELY) Completed NCT01423994 Phase 4
3 Fish Oil for Atrial Fibrillation - Effect and Mechanisms Completed NCT00552084 Phase 4 Fish oil;Placebo
4 Propranolol for Syncope With Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
5 A Prospective, Randomized, Double Blind Study Comparing the Efficacy and Safety of Fentanyl Nasal Spray to Placebo as an Analgesic, in Patients Undergoing Outpatient Cystoscopic Procedures Completed NCT01708122 Phase 4 Fentanyl;saline
6 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
7 Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment Recruiting NCT02041234 Phase 4 Incretin analogues;Xenical;SGLT2 inhibitors;DPP-4 Inhibitors
8 Effects of Perampanel on Neurophysiology Test Perimeters Recruiting NCT03653741 Phase 4 Perampanel 6 MG
9 A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Recruiting NCT02347111 Phase 4 Flecainide;Sotalol
10 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV (Post 4) Active, not recruiting NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
11 Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrillation and Flutter Completed NCT01439386 Phase 3
12 A Phase 3, 182-week, Open-Label, Safety and Tolerability Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension (snOH) in Subjects With Primary Autonomic Failure Recruiting NCT04095793 Phase 3 ampreloxetine
13 A Phase 3, 4-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure Recruiting NCT03750552 Phase 3 ampreloxetine;Placebo
14 A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects With Primary Autonomic Failure Recruiting NCT03829657 Phase 3 ampreloxetine;Placebo
15 Effects of PTH Replacement on Bone in Hypoparathyroidism Terminated NCT00395538 Phase 3 PTH 1-34
16 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After ESWL Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
17 Long-term, Open Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of QCC374 in Patients With Pulmonary Arterial Hypertension (PAH) Completed NCT02939599 Phase 2 QCC374
18 Propranolol for Syncope With Sympathoadrenal Imbalance in Children Completed NCT00093860 Phase 2 Propranolol
19 Preventing Adverse Reactions in Novice Blood Donors Completed NCT00302900 Phase 2
20 A Randomized Prospective Comparison of DDD Chamber Pacing and Percutaneous Transluminal Septal Ablation in Obstructive Hypertrophic Cardiomyopathy Associated With Severe Drug-Refractory Symptoms Completed NCT00001894 Phase 2
21 A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope (POST 6) Completed NCT02874937 Phase 2 Atomoxetine;Matching Placebo
22 The Effects of ARA290 on the Cognitive and Neural Processing of Emotions in Healthy Volunteers Completed NCT02070783 Phase 1, Phase 2 ARA290;Placebo
23 Trans-Right Ventricular Approach to Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Feasibility Study Completed NCT00035386 Phase 2
24 Controlled Cross-Over Study of DDD Pacemaker Therapy in Symptomatic Children With Obstructive Hypertrophic Cardiomyopathy Completed NCT00001960 Phase 2
25 Glutathione (GSH) In The Treatment of Parkinson's Disease Completed NCT01177319 Phase 2 Glutathione
26 A Pilot Study: Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas Completed NCT00624416 Phase 1, Phase 2 Prednisolone synthetic cortisone and Isoproterenol together
27 Non-Pharmacologic Therapy for Neurocardiogenic Syncope Completed NCT00096902 Phase 2
28 A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST 6 Completed NCT02500732 Phase 2 Atomoxetine;Placebo
29 Safety and Efficacy of Intravenous Norepinephrine for Orthostatic Hypotension Completed NCT01285908 Phase 1, Phase 2 Intravenous Norepinephrine Infusion
30 The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Pulmonary Hypertension: Initial Studies for Establishing Guidelines Completed NCT00678821 Phase 2
31 Methionine-Restriction Diet (MRD) in Obese Adults With Metabolic Syndrome Completed NCT00640757 Phase 2
32 Evaluation of the Safety and Efficacy of a Standardized Eucommia Extract in the Treatment of Hypertension Completed NCT00626132 Phase 2
33 Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma Completed NCT00273910 Phase 2 gp100:209-217 (210M);Montanide ISA-51;Imiquimod
34 Study of the Effect of Naltrexone on Cerebral Blood Flow and Hypoglycemia in Type 1 Diabetes Mellitus Completed NCT01053078 Phase 1, Phase 2 Naltrexone;Naltrexone
35 A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009) Completed NCT01797575 Phase 2 Aspirin;Sugar Pill
36 Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Recruiting NCT02558972 Phase 2 Northera (Droxidopa);Placebo;Northera (Droxidopa);Placebo
37 Microbiota-directed Complementary Food (MDCF) Trial Recruiting NCT04015999 Phase 2
38 Microbiota Directed Complementary Food (MDCF) Post-SAM MAM Trial Recruiting NCT04015986 Phase 2
39 A Randomized, Parallel-group, Placebo-controlled Subject and Investigator Blinded Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of QCC374 in the Treatment of Pulmonary Arterial Hypertension Terminated NCT02927366 Phase 2 QCC374;Placebo Matching
40 Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement Withdrawn NCT02365415 Phase 2 Sirolimus
41 A Phase 1 Dose Escalating Study of Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT) From Enterotoxigenic Escherichia Coli (ETEC) by Sublingual or Oral Immunization to Determine Safety and Immunogenicity of a Multi-dose Regimen in Adult Humans Completed NCT02052934 Phase 1
42 A Human Pilot Study to Quantify BCG From the BCG Vaccination Site, and to More Fully Characterise the Immune Response to BCG Completed NCT00653627 Phase 1
43 Reducing Orthostatic Intolerance With Oral Rehydration in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Active, not recruiting NCT02854683 Phase 1 Normal Saline
44 EXercise for the Prevention of Syncope Evaluation Suspended NCT00203593 Phase 1
45 Observational Study of the Sleuth Implantable ECG Monitoring System Unknown status NCT00717106
46 Randomized Trial of Cardiovascular Response to Two Manual Techniques Non-thrust Joint Manipulation of the Cervical Spine in Patients With Non-traumatic Mechanical Neck Pain. Unknown status NCT02198677
47 Assessment of Adverse Cardiac Events Using Local Anesthesia With Adrenaline Unknown status NCT02738567
48 Efficacy of Electro-acupuncture Versus Manual Acupuncture for Knee Osteoarthritis: a Randomized Controlled Pilot Trial Unknown status NCT03274713
49 Electro-acupuncture of Different Treatment Frequency in Knee Osteoarthritis: a Pilot Randomized Clinical Trial Unknown status NCT03359603
50 Cohort Description of Younger With AV-block Unknown status NCT03024047

Search NIH Clinical Center for Fainting

Genetic Tests for Fainting

Anatomical Context for Fainting

MalaCards organs/tissues related to Fainting:

40
Heart, Brain, Skin, Testes, Kidney, Whole Blood, Lung

Publications for Fainting

Articles related to Fainting:

(show top 50) (show all 1115)
# Title Authors PMID Year
1
When Is Syncope Arrhythmic? 42
31378326 2019
2
Does A Therapy for Reflex Vasovagal Syncope Really Exist? 42
31297720 2019
3
Treatment of syncope in tongue cancer with palliative chemotherapy in the intensive care unit: A case report. 42
31464952 2019
4
Moxibustion for the treatment of primary dysmenorrhea: Protocol for an overview of systematic reviews. 61
31977904 2020
5
HIV self-testing intervention experiences and kit usability: results from a qualitative study among men who have sex with men in the SELPHI (Self-Testing Public Health Intervention) randomized controlled trial in England and Wales. 61
31821698 2019
6
[Features of changes in volume-impedance hemodynamic indicators during the tilt test in young males with a history of vasovagal syncopes]. 61
31849297 2019
7
Outcome preferences of older people with multiple chronic conditions and hypertension: a cross-sectional survey using best-worst scaling. 61
31856842 2019
8
Late Survival and Patient-Perceived Health Status of the Congenital Heart Surgeons' Society dextro-Transposition of the Great Arteries Cohort. 61
31348901 2019
9
"Falling down": a retroperitoneal catastropheC. 61
32007116 2019
10
Expansion of the Primrose syndrome phenotype through the comparative analysis of two new case reports with ZBTB20 variants. 61
31321892 2019
11
Case Report: Fainting During Acupuncture Treatment. 61
31719213 2019
12
Gender and age differences in symptoms and health-related quality of life in patients with atrial fibrillation referred for catheter ablation. 61
31495941 2019
13
Factors that contribute to blood donation behavior among primary healthcare users: A structural approach. 61
31519527 2019
14
Mass spectrometry-based proteomics for the forensic identification of vomit traces. 61
31526901 2019
15
Interrelationships between pulse arrival time and arterial blood pressure during postural transitions before and after spaceflight. 61
31414954 2019
16
Unilateral neck pain and headache, vocal hoarseness, swallowing difficulty, and fainting attacks: a case report of idiopathic carotidynia with unusual clinical manifestations. 61
31567387 2019
17
Blood and organ donation: health impact, prevalence, correlates, and interventions. 61
31213077 2019
18
Predonation fears identify young donors at risk for vasovagal reactions. 61
31267576 2019
19
Assessment of Knowledge of Symptoms of Ischemic Heart Disease in Population Visiting a Tertiary Care Hospital in Pakistan. 61
31656711 2019
20
Mechanisms of tilt-induced vasovagal syncope in healthy volunteers and postural tachycardia syndrome patients without past history of syncope. 61
31250563 2019
21
Deep Infiltrating Endometriosis and Spontaneous Hemoperitoneum: A Life-Threatening Situation Treated by Laparoscopy. 61
31376586 2019
22
Efficacy and safety of acupuncture as an adjuvant treatment for acute pancreatitis: a protocol of systematic review and meta-analysis. 61
31278104 2019
23
Prehospital clinical presentation in patients with acute coronary syndrome complicated by cardiogenic shock: A single center study. 61
30213588 2019
24
[Facial redness and fainting after elevation of both arms in a 74 year-old man]. 61
31103242 2019
25
Quality of life improves in vasovagal syncope patients after clinical trial enrollment regardless of fainting in follow-up. 61
31122600 2019
26
Estimating the risk of blood donation fainting for self versus others: the moderating effect of fear. 61
30828820 2019
27
Atypical Prodromal Symptoms Help to Distinguish Patients With Psychogenic Nonsyncopal Collapse Among Youth Referred for Fainting. 61
30922770 2019
28
[New Targets in Blood Pressure Control: Arguments Pro and Contra]. 61
31131773 2019
29
Childhood poly-victimization and children's health: A nationally representative study. 61
30852428 2019
30
Overview of a Knowledge Translation (KT) Project to improve the vaccination experience at school: The CARD™ System. 61
30948918 2019
31
Involving stakeholders in informing the development of a Knowledge Translation (KT) intervention to improve the vaccination experience at school. 61
30948919 2019
32
Stakeholder feedback on The CARD™ System to improve the vaccination experience at school. 61
30948920 2019
33
[Effects on urinary retention after spinal cord injury treated with acupuncture at Zhibian (BL 54) and Shuidao (ST 28) with elongated needle]. 61
30957445 2019
34
Piloting The CARD™ System for education of students about vaccination: Does it improve the vaccination experience at school? 61
30948921 2019
35
The Fainting Assessment Inventory: A 10-Item Instrument Developed to Screen for Psychogenic Nonsyncopal Collapse Among Youth Referred for Syncope. 61
30921250 2019
36
Intermittent calf compression reverses lower limb pooling and improves cardiovascular control during passive orthostasis. 61
30638840 2019
37
Putting the Spirit into Culturally Responsive Public Health: Explaining Mass Fainting in Cambodia. 61
29956053 2019
38
Fear of blood, injections and fainting as barriers to blood donation in Brazil. 61
30485453 2019
39
A case of acute organic solvent poisoning during epoxy coating. 61
31543970 2019
40
[Follow-up of Patients with Cardiac Pacemakers]. 61
30890083 2019
41
Genetic and Environmental Factors Contributing to Parkinson's Disease: A Case-Control Study in the Cypriot Population. 61
31681140 2019
42
The Search for the Genes of Vasovagal Syncope. 61
31850372 2019
43
HPV vaccine confidence and cases of mass psychogenic illness following immunization in Carmen de Bolivar, Colombia. 61
30118381 2019
44
Effects of Breath-Hold Deep Diving on the Pulmonary System. 61
30783070 2019
45
Are the health needs of children with disabilities being met at primary schools? 61
30621499 2019
46
Abdominal Pregnancy: A Case Report of a Viable Nondysmorphic Fetus. 61
31413435 2019
47
Collapse in the scrum. 61
29507049 2018
48
Sleep Fainting: A Neurocardiogenic Entity. 61
30820371 2018
49
Ammonia Inhalation Does Not Increase Deadlift 1-Repetition Maximum in College-Aged Male and Female Weight Lifters. 61
30480652 2018
50
Autonomic dysfunction and HPV immunization: an overview. 61
30478703 2018

Variations for Fainting

Expression for Fainting

Search GEO for disease gene expression data for Fainting.

Pathways for Fainting

Pathways related to Fainting according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.16 VWF F8
2 10.78 VWF F8

GO Terms for Fainting

Cellular components related to Fainting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 VWF F8

Biological processes related to Fainting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.32 VWF F8
2 platelet degranulation GO:0002576 9.26 VWF F8
3 platelet activation GO:0030168 9.16 VWF F8
4 hemostasis GO:0007599 8.96 VWF F8
5 blood coagulation, intrinsic pathway GO:0007597 8.62 VWF F8

Sources for Fainting

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....